1-BOC-4-(2-吡啶甲基)哌嗪 | 77278-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-BOC-4-(2-吡啶甲基)哌嗪
• 中文别名: 1-(叔丁氧基羰基)-4-((2-吡啶)甲基)哌嗪
• 英文名称: 1-(tert-butoxycarbonyl)-4-((2-pyridyl)methyl)piperazine
• 英文别名: t-butyl 4-(pyridin-2-ylmethyl)piperazine-1-carboxylate；4-pyridin-2-ylmethyl-piperazine-1-carboxylic acid tert-butyl ester；1-(tert-butoxycarbonyl)-4-[(pyridin-2-yl)methyl]piperazine；tert-butyl 4-(pyridine-2-ylmethyl)piperazine-1-carboxylate；1-(tert-butoxycarbonyl)-4-[(2-pyridyl)methyl]piperazine；tert-butyl 4-((Pyridin-2-yl)methyl)piperazine-1-carboxylate；tert-butyl 4-(pyridin-2-ylmethyl)piperazine-1-carboxylate
• CAS: 77278-93-4
• 化学式: C₁₅H₂₃N₃O₂
• 分子量: 277.367
• InChiKey: YKGYLSBMOUSMDS-UHFFFAOYSA-N

物化性质

• 沸点：
  369.0±37.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-BOC-4-(2-吡啶甲基)哌嗪 在 盐酸 、 1-羟基苯并三唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 氯仿 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 86.0h， 生成 1-(3-amino-3-phenylpropionyl)-4-[(2-methyl-pyridin-3-yl)cyanomethyl]piperazine
  参考文献：
  名称：

  Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists

  摘要：

  A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)-piperazines, with increased oral activity was prepared and evaluated in vitro in a PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP). Oral activity was ascertained through a PAF-induced mortality test in mice (MOR). Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test. Three different types of acyl substituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups. The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 muM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR- 12519, PAG IC50 = 0.041 muM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086. Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests. On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.

  DOI：

  10.1021/jm00072a019
• 作为产物：
  描述：

  2-氯甲基吡啶盐酸盐 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 42.0h， 生成 1-BOC-4-(2-吡啶甲基)哌嗪
  参考文献：
  名称：

  Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists

  摘要：

  A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)-piperazines, with increased oral activity was prepared and evaluated in vitro in a PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP). Oral activity was ascertained through a PAF-induced mortality test in mice (MOR). Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test. Three different types of acyl substituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups. The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 muM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR- 12519, PAG IC50 = 0.041 muM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086. Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests. On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.

  DOI：

  10.1021/jm00072a019

文献信息

• [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR ß3-ADRÉNERGIQUE DÉRIVÉS DE LA PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012012314A1

  公开（公告）日：2012-01-26

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).

  本发明提供了式(I)的化合物，其药物组成物以及使用这些化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors
  作者：Ming-xin Dong、Lu Lu、Haitao Li、Xiaohua Wang、Hong Lu、Shibo Jiang、Qiu-yun Dai

  DOI：10.1016/j.bmcl.2012.03.019

  日期：2012.5

  A series of novel 1,4-disubstituted piperidine/piperazine derivatives were designed, synthesized and evaluated for their in vitro activities against HIV-1 Bal (R5) infection in CEMX174 5.25M7 cells. A majority of these compounds showed potent anti-HIV-1 activities with IC at nanomolar levels. -(4-Fluoro-benzyl)piperazine analog hydrochloride exhibited potency against HIV-1 activity similar to that of

  设计、合成了一系列新型 1,4-二取代哌啶/哌嗪衍生物，并评估了它们在 CEMX174 5.25M7 细胞中抗 HIV-1 Bal (R5) 感染的体外活性。大多数这些化合物显示出有效的抗 HIV-1 活性，IC 为纳摩尔水平。 -(4-氟苄基)哌嗪类似物盐酸盐表现出与 TAK-220 盐酸盐相似的抗 HIV-1 活性，但它具有更好的水溶性（25°C 磷酸钠缓冲液中 25mg/ml）和口服生物利用度(56%) 高于 TAK-220 盐酸盐（溶解度为 2mg/ml，口服生物利用度为 1.4%）。这些结果表明，盐酸盐可以作为开发新的抗 HIV-1 疗法或治疗和预防 HIV-1 感染的杀菌剂的更好先导物。
• (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
  申请人：J. URIACH & CIA. S.A.

  公开号：EP0528172A1

  公开（公告）日：1993-02-24

  The present invention relates to new (2-alkyl-3-pyridyl)methylpiperazine derivatives of general formula I: wherein R¹, R² and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.

  本发明涉及一般式I的新(2-烷基-3-吡啶基)甲基哌嗪衍生物，其中R¹，R²和Z如权利要求1所定义。该发明还涉及它们的制备方法以及含有它们的药物组合物。这些化合物是有效的口服PAF拮抗剂，因此它们在治疗涉及该物质的疾病中很有用。
• [EN] PIPERAZINE DERIVATIVES FOR TREATING DISORDERS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE POUR LE TRAITEMENT DE TROUBLES
  申请人：UNIV NOTTINGHAM

  公开号：WO2015159103A1

  公开（公告）日：2015-10-22

  Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

  描述了抗血管生成治疗、高通透性疾病治疗、神经病理性和神经退行性疾病治疗、疼痛治疗、降低子痫前期风险的方法以及用于这些方法的化合物。
• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。